ATLANTA, Aug. 30, 2007 (PRIME NEWSWIRE) -- OTC Stock Review and Amex Review announced today that coverage has been initiated on AMDL, Inc. (AMEX:ADL). AMDL, Inc., headquartered in Tustin, California, owns China's Jade Pharmaceutical, Inc., is currently seeking FDA approval of its DR-70 non-invasive cancer blood test, and has a Combination Immunogene Therapy ("CIT") technology that could lead to a vaccine or possibly treat those already diagnosed with cancer.
The complete report on AMDL, Inc. is available at
http://www.amexreview.com/Files/ADL/ADL_Review.pdf or http://www.otcstockreview.com/Files/ADL/ADL_Review.pdf.
Additionally, more information on AMDL, Inc. is available at http://www.amdl.com.
Jade Pharmaceutical, Inc. offers investors an excellent play on the expanding Chinese economy with its ownership of Jade Pharmaceutical, Inc. Through its two operating subsidiaries, Jiangxi Jiezhong Bio-chemical Company Ltd. and Yanbian Yiqiao Biochemistry Pharmacy Co. Ltd., Jade Pharmaceutical has over 130 licenses to produce pharmaceuticals in China.
The DR-70(r) ELISA Kit for Cancer: DR-70(r) is ADL's proprietary diagnostic test kit for cancer. Studies have shown that the DR-70(r) can monitor and detect at least 14 different types of cancer including: lung (small and non-small cell); stomach; breast; rectal; colon and liver. As DR-70(r) is a non-invasive blood test, there are no side effects. DR-70(r) has been shown to be useful in monitoring patients after cancer treatment to detect a recurrence of their cancer. DR-70(r) is not yet cleared for sale in the United States, however, AMDL, Inc. will be presenting information requested by the FDA as a part of the plan to gain marketing approval of DR-70(r) to monitor colon cancer in the United States.
AMDL, Inc. also owns a Combination Immunogene Therapy (CIT) technology that in Phase I clinical trials was shown to be effective in treating cancer. This product could lead to an effective treatment for various types of cancer and cancer vaccines. On May 25, 2004, AMDL received a United States Patent for CIT. AMDL, Inc.'s CIT technology has been shown to be effective in enhancing a cancer patient's immune system to attack and kill cancer cells. CIT technology may lead to vaccines to protect patients known to be at risk due to a family history for certain types of cancer. AMDL, Inc.'s operating strategy is focused on locating a pharmaceutical or biotechnology strategic partner to license its CIT technology, or form a joint venture. Two potential partners with whom the company has started strategic alliance discussions are IPIX and the Academy of Military and Medical Sciences.
NOTE: The purpose of this release is to introduce the reader to OTC Stock Review and Amex Review and AMDL, Inc. OTC Stock Review and Amex Review are not Registered Investment Advisors or Broker/Dealers. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice. This document contains information obtained from public sources about AMDL, Inc., but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of AMDL, Inc., as profiled. OTC Stock Review and Amex Review have been compensated $10,500 to perform investor relations services for AMDL, Inc. and officers, directors, and employees of OTC Stock Review and Amex Review may hold a long or short equity position of a profiled company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review and Amex Review are not liable for any investment decisions by its readers or their advisors. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm